Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: PR Newswire
PRINCETON, N.J., April 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued treatment with SGX301 (synthetic hypericin) twice weekly for 12 weeks increased the positive response rate to 40% (pSoligenix previously announced positive top-line results when the study achieved statistical significance (p=0.04) in its primary endpoint over the first 6 week double-blind treatment cycle (referred to as Cycle 1) (available here). The study enrolled 169 patients randomized 2:1 to receive either SGX301 or placebo in Cycle 1. After the subsequent additional 6-week treatment in the open-label Cycle 2, the response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold. Treatment responses for each cycle were assessed at Week 8 (after 6 weeks of
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa [Yahoo! Finance]Yahoo! Finance
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaPR Newswire
- Soligenix Announces Pricing of $4.75 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces Pricing of $4.75 Million Public OfferingPR Newswire
- Why Is Penny Stock Soligenix Trading Higher On Monday? [Yahoo! Finance]Yahoo! Finance
SNGX
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- 4/22/24 - Form 8-K
- SNGX's page on the SEC website